Top Updates Back
Astellas Pharma Inc.
アステラス製薬株式会社
Astellas Pharma Ges.m.b.H Alias
Astellas Pharma a/s Alias
Astellas Pharma Korea, Inc. Alias
Astellas Farma Mexico Alias
Astellas Pharma d.o.o. Alias
Astellas Pharma AB Alias
Astellas Pharma AG Alias
Astellas Pharma LLC Alias
2005-04-01
4503
TYO
Japan
Cancer therapeutics
Urological therapeutics
Ophthalmic therapeutics
Transplant immunology therapeutics
Women's health products
Digital health solutions (Rx+ business creation, HealthX)
Products
Pipeline
Tokyo
Naoki Okamura
100,000,000,000 JPY　(1,000 100 millionJPY)
3,000 people
14,000 people
Company name
Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Astellas Farma Brasil Importacao e Distribuicao de Medicamentos Ltda.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Farma Chile SpA
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Farma Colombia S.A.S.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Farma Limitada
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma (Thailand) Co., Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Australia Pty Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma B.V.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Canada, Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Capability Centre India Private Limited
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Capability Centre Poland Sp. z o.o.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Co., Limited
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma EOOD
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Europe Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma GmbH
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Hong Kong Co., Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma India Private Limited
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma International B.V.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Malaysia Sdn. Bhd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Philippines, Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma S.p.A.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Singapore Pte. Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Sp. z o.o.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Taiwan, Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma US, Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Vietnam LLC
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma s.r.l.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma s.r.o.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas PharmaS.A.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharmaceuticals AEBE
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas d.o.o.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Belgium Astellas Pharma B.V.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
P.T. Astellas Pharma Indonesia
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Kft.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma Korea,Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Astellas Pharma ilac Ticaret ve Sanayi A.S.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Iveric Bio
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance
Absci Corporation
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Avara Norman Pharmaceutical Services, Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Aventis (現 Sanofi S.A.)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Bayer HealthCare AG (現 Bayer AG)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Bayer Pharma AG (現 Bayer AG)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
BioMarin Pharmaceutical Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Centogene N.V. (現 Crown LiquidationCo N.V.)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Charles River Laboratories International, Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Cyclerion Inc. (現 Cyclerion Therapeutics Inc.)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Ergomed Group Limited
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Fate Therapeutics, Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Genzyme Corporation (現 Sanofi S.A.)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Goethe University Frankfurt
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Hoechst Marion Roussel (現 Sanofi S.A.)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
ImmunoGen Inc. (現 AbbVie Inc.)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
KDDI株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Keryx Biopharmaceuticals, Inc. (現 Akebia Therapeutics, Inc.)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
LogicBio Therapeutics, Inc. (現 Alexion Pharmaceuticals, Inc.)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Nippon Medical & Pharmaceutical Co., Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
OSI Pharmaceuticals, Inc
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
OSI Pharmaceuticals社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
OSI ファーマシューティカルズ Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Proteostasis Therapeutics, Inc. (現 Janssen Pharmaceutica N.V.)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Sanofi-Aventis (現 Sanofi S.A.)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Shire plc
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
TREホールディングス株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Takeda Pharmaceutical Company, Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Takeda Teba Pharma Co., Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Takeda Teba Pharmaceutical Co., Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
すかいらーく
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
アステラス ファーマ グローバル ディベロップメント Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
アステラス ファーマ ヨーロッパ B.V.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
アステラス ファーマ ヨーロッパ Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
アストラゼネカ
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
エクシオグループ株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
シエーリングAG
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
ジョンソン・エンド・ジョンソン株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
バイエル
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
プロクター・アンド・ギャンブル
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
マイクロソフト
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
ユーシービージャパン株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
レゾナック・ホールディングス
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
ワイヤレスブロードバンド企画株式会社(現 UQコミュニケーションズ株式会社)
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
北京安斯泰来医药有限公司
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
北京安斯泰来医薬有限公司上海分公司
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
国立研究開発法人産業技術総合研究所
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
国際電信電話株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
安斯泰来(中国)投资有限公司上海分公司
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
安斯泰来制药(中国)有限公司
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
山之内製薬株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
日医工株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
日本ヒルティ株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
日本マイクロソフト株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
武田テバファーマ株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
武田テバ薬品株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
武田薬品工業株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
藤沢薬品工業株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders

63 entries
DateDescription
1894 Fujisawa Pharmaceutical Industries, established in 1894.
1897 Tomoyoshi Fujisawa founded Fujisawa Store in Osaka.
1923 Yamanouchi Pharmaceutical, established in 1923.
1923 Released camphor as a household insect repellent and deodorizer.
1940 Kenji Yamanouchi founded Yamanouchi Pharmaceutical Merchants in Osaka, which was later renamed Yamanouchi Pharmaceutical Inc.
1940 Renamed to Yamanouchi Pharmaceutical Inc. in 1940.
1940 Founded Yamanouchi Pharmaceutical Merchants in 1940.
1940 Kenji Yamanouchi founded Yamanouchi Pharmaceutical Merchants in Osaka.
1942 Yamanouchi Pharmaceutical moved its headquarters to Tokyo.
1942 Moved headquarters to Tokyo in 1942.
1942 Moved headquarters to Tokyo in 1942.
1942 Renamed Yamanouchi Pharmaceutical Merchants to Yamanouchi Pharmaceutical Inc.
1942 Moved Yamanouchi Pharmaceutical Merchants' headquarters to Tokyo.
1943 Renamed to Fujisawa Pharmaceutical Industries Inc.
1960 Tomoyoshi Fujisawa founded Fujisawa Store in Osaka.
1964 Completed Fujisawa Pharmaceutical Industries' Central Research Institute.
1970 Yamanouchi Pharmaceutical launched the antibiotic josamycin.
1971 Fujisawa Pharmaceutical Industries launched the injectable antibiotic cefamidine.
1977 Fujisawa Pharmaceutical Industries established Fujisawa Pharmaceutical, Corp. in the United States.
1979 Fujisawa Pharmaceutical Industries opened its first European office in London.
1981 Yamanouchi Pharmaceutical launched the antihypertensive drug perdigine.
1983 Completed Fujisawa Pharmaceutical Industries' Tsukuba Research Institute.
1985 Yamanouchi Pharmaceutical launched the H2 receptor antagonist Gaster, now sold in over 100 countries.
1986 Yamanouchi Pharmaceutical established Yamanouchi Ireland Co., Ltd. in Europe, its first overseas active ingredient manufacturing site.
1989 Completed Yamanouchi Pharmaceutical's Tsukuba Research Institute.
1990 Yamanouchi Pharmaceutical acquired the pharmaceutical division of Royal Hist Brokades in the Netherlands.
1991 Fujisawa Pharmaceutical Industries established Fujisawa Europe GmbH in Germany.
1993 Yamanouchi Pharmaceutical launched the urinary disorder improvement drug Harunair, now sold in over 90 countries.
1993 Yamanouchi Pharmaceutical launched the urinary disorder improvement drug Harunair, now sold in over 90 countries; Fujisawa Pharmaceutical Industries launched the immunosuppressant Prograf, now sold in about 100 countries.
1994 Yamanouchi Pharmaceutical established Shenyang Yamanouchi Pharmaceutical Co., Ltd. in China.
1998 Fujisawa Pharmaceutical Industries reorganized its U.S. operations and established Fujisawa Healthcare, Inc.
1999 Fujisawa Pharmaceutical Industries launched the atopic dermatitis treatment Protopick, now sold in about 60 countries.
2000 Released the hypercholesterolemia treatment Lipitol.
2001 Yamanouchi Pharmaceutical established Yamanouchi Pharma America Inc. in the United States as its own sales site.
2004 Yamanouchi Pharmaceutical launched the overactive bladder treatment Beshicare in Europe, and it was also launched in the United States in 2005.
2004 Yamanouchi Pharmaceutical launched the overactive bladder treatment Beshicare in Europe, and it was also launched in the United States in 2005; integrated the generic pharmaceutical businesses of both companies and established Zeparma.
2005 Yamanouchi Pharmaceutical established Yamanouchi Ireland Co., Ltd. in Europe.
2005 Yamanouchi Pharmaceutical established Shenyang Yamanouchi Pharmaceutical Co., Ltd. in China.
2005 Fujisawa Pharmaceutical Industries reorganized its U.S. operations and established Fujisawa Healthcare, Inc.
2005 Yamanouchi Pharmaceutical established Yamanouchi Pharma America Inc. in the United States.
2005 The two companies integrated their generic pharmaceutical businesses and established Zeparma.
2005 Integrated the generic pharmaceutical businesses of both companies and established Zeparma.
2005 Astellas Pharma Inc. was founded through the merger of the former Yamanouchi Pharmaceutical and the former Fujisawa Pharmaceutical Industries.
2005-04 Astellas Pharma was founded through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical Industries.
2005-04 Astellas Pharma celebrated its 20th anniversary in April 2005.
2005-04 Yamanouchi Pharmaceutical's urology and synthetic technologies merged with Fujisawa Pharmaceutical Industries' transplant, immunology, and fermentation technologies.
2005-04 Established Fujisawa Pharmaceutical, Corp. in the United States.
2005-04 Astellas was established in April 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical.
2005-04 Founded in April 2005. Astellas was founded in April 2005 through the merger of Yamanouchi Pharmaceutical, established in 1923, and Fujisawa Pharmaceutical Industries, established in 1894. The strengths of Yamanouchi Pharmaceutical's urology and synthetic technologies and Fujisawa Pharmaceutical Industries' transplant, immunology, and fermentation technologies merged to form an optimal complementary partnership.
2005-04 Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical Industries merged in April 2005, founding Astellas.
2005-04 Astellas Pharma Inc. was founded through the merger of the former Yamanouchi Pharmaceutical and the former Fujisawa Pharmaceutical Industries.
2006 Transferred Zeparma, a company engaged in generic pharmaceuticals, to Daiichi Sankyo Co., Ltd.
2007 Released the quinolone oral synthetic antibacterial Geninack™ in Japan. Acquired the U.S. biotech venture Agensys.
2007 Released the quinolone oral synthetic antibacterial Geninack™ in Japan. Acquired the U.S. biotech venture Agensys.
2010 Acquired the U.S. pharmaceutical company OSI Pharmaceuticals.
2011 Released the overactive bladder treatment Betanis™ in Japan. Signed the UN Global Compact.
2011 Released the overactive bladder treatment Betanis™ in Japan. Signed the UN Global Compact.
2012 Installed wind power at the Kerry plant in Ireland and started operation of a wood biomass boiler. Participated in a new public-private partnership for developing schistosomiasis treatment for preschool children. Launched the prostate cancer treatment XTANDI™ in the United States.
2012 Installed wind power at the Kerry plant in Ireland and started operation of a wood biomass boiler. Participated in a new public-private partnership for developing schistosomiasis treatment for preschool children. Launched the prostate cancer treatment XTANDI™ in the United States.
2025-04 In April 2025, Astellas celebrated its 20th anniversary as a company.
2025-04 Astellas Pharma celebrated its 20th anniversary in April 2025. Astellas was founded in April 2005 through the merger of Yamanouchi Pharmaceutical, established in 1923, and Fujisawa Pharmaceutical Industries, established in 1894.
2025-04 Astellas Pharma celebrated its 20th anniversary in April 2025.
2025-04 Astellas Pharma celebrated its 20th anniversary in April 2025.
+ Loaded when opened
5010001034966
Trade nameアステラス製薬株式会社
Trade name (kana)アステラスセイヤク
Name in English
Corporation type301
Address〒103-0023 東京都中央区日本橋本町２丁目５番１号
Postal code1030023
Prefecture code13
City code102
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date2015-10-05
Update date2023-12-14
Change date2022-04-01
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change令和４年４月１日東京都中央区日本橋本町二丁目５番１号アステラスファーマテック株式会社（7010001139549）を合併令和４年４月１日東京都中央区日本橋本町二丁目５番１号アステラスグリーンサプライ株式会社（4010001092817）を合併
Latest record1
Excluded from search0
Processing type71
Correction type1
Trade name image ID
Address image ID
Sequence number1866231
Source: National Tax Agency Corporate Number Publication Site, basic three items
5010001034966
Corporate number5010001034966
Trade nameアステラス製薬株式会社
Trade name (kana)アステラスセイヤク
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address東京都中央区日本橋本町２丁目５番１号
Postal code1030023
Prefecture東京都
Prefecture code13
City or district中央区
City code102
Street address日本橋本町２丁目５番１号
Organisation type301
Processing type71
Correction type1
Status
Representative代表取締役社長　岡村　直樹
Capital103001000000
Employees4948
Employees (male)3182
Employees (female)1393
Business summary医薬品の製造・販売および輸出入
Website URLhttp://www.astellas.com/jp/
Year founded
Business categoryE:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date2023-12-14
Key information5010001034966
Source: gBizINFO (Ministry of Economy, Trade and Industry)
✅
2026-09-21 23:34 (Model: ggml-org/gpt-oss-20b )
↑